
GRDN Stock Forecast & Price Target
GRDN Analyst Ratings
Bulls say
Guardian Pharmacy Service is viewed positively because it is the clear leader in a fragmented LTC pharmacy market, with 13% national share, over 200,000 residents served, and a purpose-built model for assisted living that creates scale, pricing, and service advantages versus smaller peers. Its outlook is further supported by durable demographic demand as baby boomers age into assisted living, plus a three-pronged growth engine that can drive high-single-digit organic growth through deeper penetration, new contracts, and greenfield expansion. Financially, the company’s balance sheet is a strength, with about $90 million of cash, no debt, ~60% cash conversion, and best-in-class ex-cash ROIC of roughly 35%-40%, while 2024 and 2025 acquisitions and openings representing ~10% of revenue could add a 3%-4% EBITDA tailwind in 2027 and 2028.
Bears say
Guardian Pharmacy Service is facing a structurally weaker reimbursement backdrop as the IRA and CMS pricing changes push certain high-cost branded drugs toward Maximum Fair Prices, which can fall below pharmacies’ acquisition costs and compress margins even after manufacturer true-ups. The pressure is especially relevant in long-term care, where profitability has historically depended on branded drugs despite them representing only about 10% of volume, while generic drugs make up roughly 90% of volume and earn breakeven margins. In addition, the bankruptcy of Omnicare in September 2025 highlights regulatory and reimbursement vulnerability across the sector, while risks around staffing, PBM contracts, facility integration, and reliance on technology assets add further downside to fundamentals.
This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares